We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
HLXO | Helix Resources Limited | 0.002 | 0.001 | 100.00% | 1,500,000 | 3 |
AXP | AXP Energy Limited | 0.002 | 0.001 | 100.00% | 45,000 | 2 |
ESROB | Estrella Resources Limited | 0.002 | 0.001 | 100.00% | 2,000,000 | 1 |
FRSO | Forrestania Resources Ltd | 0.002 | 0.001 | 100.00% | 228,500 | 4 |
AS2O | Askari Metals Ltd | 0.01 | 0.005 | 100.00% | 53,333 | 1 |
FRSOB | Forrestania Resources Ltd | 0.015 | 0.005 | 50.00% | 3,778,207 | 25 |
BUYO | Bounty Oil & Gas | 0.003 | 0.001 | 50.00% | 1,025,000 | 2 |
AUK | Aumake Limited | 0.003 | 0.001 | 50.00% | 1,017,000 | 4 |
W2VO | Way 2 Vat Ltd | 0.003 | 0.001 | 50.00% | 1,633,333 | 3 |
VMSO | Venture Minerals Ltd | 0.01 | 0.003 | 42.86% | 4,243,903 | 13 |
IS3 | I Synergy Group Limited | 0.014 | 0.004 | 40.00% | 44,000 | 1 |
As previously reported, the Board of Directors (the “Board”) of Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) approved the repurchase of up to $5 million of the Company’s outstanding common stock from time to time in the open market at prevailing market prices or in privately negotiated transactions (the “Stock Repurchase Program”). The Company today announced that the Board is conducting a strategic review to determine whether it is appropriate to increase the maximum amount that can be repurchased pursuant to the Stock Repurchase Program based on the amount, if any, of excess funds that may be ...
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas, May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming 2024 BIO International Convention.
First Quarter Fiscal 2025 Total Revenue of $450.6 million, up 22% Year-over-Year Continued Strong Customer Growth with Over 49,200 Customers as of April 30, 2024 MongoDB Atlas Revenue up 32% Year-over-Year; 70% of Total Q1 Revenue NEW YORK, May 30, 2024 /PRNewswire/ -- MongoDB, Inc. (NASDAQ: MDB) today announced its financial results for the first quarter ended April 30, 2024.
Atlanta Postal Credit Union (APCU), Georgia’s oldest credit union and the largest postal credit union in the United States, along with its community-based subsidiary, Center Parc Credit Union, and Affinity Bancshares, Inc (“Affinity”) (NASDAQ: AFBI) announced today that APCU has entered into a definitive agreement pursuant to which the credit union will acquire Covington, Georgia-based Affinity Bank, National Association, a wholly-owned subsidiary of Affinity. The transaction is structured as a purchase and assumption agreement whereby APCU will acquire Affinity Bank by purchasing substantially all assets and assuming substantially all liabilities of Affinity Bank in an all-cash transaction.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 67,705.97 | -19.47 | -0.03% | 1.33T | 1,068,416,955 |
ETH | Ethereum | 3,804.40 | -8.07 | -0.21% | 457.55B | 1,237,473,129 |
USDT | Tether USD | 0.99916 | -0.00003 | 0.00% | 97.76B | 54,998,573 |
BNB | Binance Coin | 602.81 | 1.54 | 0.26% | 95.31B | 150,254,645 |
SOL | Solana | 166.00 | 0.00 | 0.00% | 73.2B | 321,578,488 |
STETH | stETH | 3,802.41 | -7.77 | -0.20% | 37.33B | 3,369,322 |
XRP | Ripple | 0.5175 | -0.0007 | -0.14% | 28.26B | 83,661,689 |
USDC | USD Coin | 1.00 | 0.00002 | 0.00% | 28.07B | 254,272,388 |
DOGE | Dogecoin | 0.15939 | -0.00086 | -0.54% | 22.88B | 123,623,339 |
TONCOIN | Wrapped TON Coin | 6.33 | 0.026453 | 0.42% | 21.88B | 39,596,537 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions